| Availability: | |
|---|---|
INCI Name | Tripeptide-29 |
CAS Number | 2239-67-0 |
Appearance | White to yellowish powder |
PH | 4.0–6.0 (1 mg/ml, H₂O) |
Recommended Dosage | 0.005%–0.03% |
Storage | Refrigerated (5±3°C), dry, and sealed. |
Scientific Mechanism & Efficacy Data
WKPep®Mini-collatide functions as a biomimetic signaling peptide that binds to fibroblast surface receptors, activating intracellular pathways that upregulate procollagen gene transcription. In vitro studies confirmed that within the concentration range of 50–500 ppm, WKPep®Mini-collatide significantly increased Type I collagen content in human skin fibroblasts (HSF), achieving a maximum increase of 59.74% compared to the control group (###p < 0.001). Additionally, it demonstrated no cytotoxic effects on HSF cells across a wide concentration range (1–1000 ppm) and improved the viability of UVB-damaged cells, with statistically significant recovery at 50 ppm (*p < 0.05), 200 ppm (p < 0.01), and 500 ppm (*p < 0.001) versus the UVB-only group.
In a 14-day clinical study, 33 participants (aged 30–60, with baseline facial R-value < 0.65) applied an emulsion containing 200 ppm WKPep®Mini-collatide twice daily. Compared to the placebo group, the active group demonstrated significant improvements in skin elasticity: R2 (gross elasticity) increased by 14.54%, R7 (viscoelasticity) by 14.37%, and Q1 (resilience) by 14.63% (###p < 0.001). These multi-dimensional elasticity gains confirm that WKPep®Mini-collatide effectively restores biomechanical properties—reducing sagging and promoting a firmer, more youthful skin appearance. Its ultra-low effective dosage, combined with robust safety and clinical validation, positions WKPep®Mini-collatide as a powerful and versatile ingredient for premium anti-aging applications.